BioDlink International Company Limited
BioDlink International Company Limited Fundamental Analysis
BioDlink International Company Limited (1875.HK) shows moderate financial fundamentals with a PE ratio of -33.44, profit margin of -13.27%, and ROE of -14.53%. The company generates $0.7B in annual revenue with strong year-over-year growth of 40.70%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 19.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 1875.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak1875.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent1875.HK trades at attractive valuation levels.
Growth Score
Moderate1875.HK shows steady but slowing expansion.
Financial Health Score
Excellent1875.HK maintains a strong and stable balance sheet.
Profitability Score
Weak1875.HK struggles to sustain strong margins.
Key Financial Metrics
Is 1875.HK Expensive or Cheap?
P/E Ratio
1875.HK trades at -33.44 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 1875.HK's PEG of 0.03 indicates potential undervaluation.
Price to Book
The market values BioDlink International Company Limited at 5.27 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -41.53 times EBITDA. This is generally considered low.
How Well Does 1875.HK Make Money?
Net Profit Margin
For every $100 in sales, BioDlink International Company Limited keeps $-13.27 as profit after all expenses.
Operating Margin
Core operations generate -12.05 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-14.53 in profit for every $100 of shareholder equity.
ROA
BioDlink International Company Limited generates $-7.83 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
BioDlink International Company Limited produces operating cash flow of $123.43M, showing steady but balanced cash generation.
Free Cash Flow
BioDlink International Company Limited produces free cash flow of $48.42M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.07 in free cash annually.
FCF Yield
1875.HK converts 1.47% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-33.44
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.03
vs 25 benchmark
P/B Ratio
Price to book value ratio
5.27
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.44
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.61
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.05
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.15
vs 25 benchmark
ROA
Return on assets percentage
-0.08
vs 25 benchmark
ROCE
Return on capital employed
-0.09
vs 25 benchmark
How 1875.HK Stacks Against Its Sector Peers
| Metric | 1875.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -33.44 | 28.31 | Better (Cheaper) |
| ROE | -14.53% | 699.00% | Weak |
| Net Margin | -13.27% | -130884.00% (disorted) | Weak |
| Debt/Equity | 0.61 | 0.34 | Weak (High Leverage) |
| Current Ratio | 2.05 | 2775.16 | Strong Liquidity |
| ROA | -7.83% | -14469.00% (disorted) | Weak |
1875.HK outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews BioDlink International Company Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
1805.33%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
108.25%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
136.40%
Industry Style: Defensive, Growth, Innovation
High Growth